The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function — H-21044858  

Incretin Effect Clinical Trial

Official title: The Effect of Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon-like Peptide-1 (GLP-1) and Glucagon-like Peptide-2 (GLP-2) in Individuals With Genetically Altered Receptor Function

Status Recruiting

Clinical Trial Summary

This project will characterize the physiological effect of the hormones, GIP-, GLP-1- and GLP-2 infusions in a group of individuals that are carriers of GIP-, GLP-1- and GLP-2 receptor gene variants, respectively.

Clinical Trial Description

Participants with mutations in their GLP-1- and GIP receptor will attend five randomized experimental days, A1, A2, B, C and D. On day A1 an oral glucose tolerance test (OGTT) will be performed, and on day A2, an intravenous isoglycaemic glucose infusion (IIGI) will be performed. On experimental day B and C, the study participants will receive GLP-1 and GIP hormones, respectively, under stable glucose infusions and on experimental day D, they will receive infusion of salt water (placebo) under stable glucose infusion.

Participants with mutations in their GLP-2 receptor will attend three randomized experimental days, E, F and G. A mixed meal test (MMT) will be performed on day E, an infusion with GLP-2 during fasting blood glucose levels will be performed on day F, and infusion with salt water (placebo) during fasting blood glucose levels will be performed on day G.

Additionally, a DXA scan and arginine test will be performed on all study participants. ;

Related Conditions & MeSH terms

• Incretin Effect

• NCT number: NCT06194955
• Study type: Interventional
• Source: University of Copenhagen
• Contact: Lærke S Gasbjerg, MD, PhD
• Phone: +45 35322626
• Email: lsg@sund.ku.dk
• Status: Recruiting
• Phase: N/A
• Start date: January 4, 2023
• Completion date: December 2027